Will Sarepta Be Bought Out in 2013?

Many investors remember that legendary day in September when shares of then little-known biotech Sarepta climbed almost 200% in a single day. The promise behind the company's Duchenne muscular dystrophy drug eteplirsen has generated massive interest in the stock and might have some investors thinking that this is a prime buyout target for big pharma players searching for lucrative drugs.

But wait -- is Sarepta actually looking for an acquirer?

In this video, health care analyst Max Macaluso weighs in on the debate and gives his opinion on whether this fledgling biotech will be acquired.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article Will Sarepta Be Bought Out in 2013? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.